Episode
Episode 198 - Andrew Obenshain - CEO Inventiva
- Podcast
- The BioHub - by Avetix
- Published
- Jul 10, 2026
- Duration seconds
- 1548
- Processing state
not_requested- Canonical source
- https://podcasters.spotify.com/pod/show/max-brennan4/episodes/Episode-198---Andrew-Obenshain---CEO-Inventiva-e3lt7dk
Actions
POST https://stenobird.com/v1/public/podcasts/the-biohub-by-avetix-7252289/episodes/episode-198-andrew-obenshain-ceo-inventiva/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/the-biohub-by-avetix-7252289/episode-198-andrew-obenshain-ceo-inventiva.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
In this episode of The BioHub Podcast , Max sits down with Andrew Obenshain, CEO of Inventiva. Andrew brings more than 20 years of experience across global drug development, regulatory strategy, and commercialization. Before joining Inventiva, he led bluebird bio through its transformation into a global commercial-stage gene therapy company and previously held senior leadership roles at Shire and Genzyme. Inventiva is a late-stage clinical biopharmaceutical company developing oral therapies for patients with significant unmet medical needs, with its lead program focused on MASH (metabolic dysfunction-associated steatohepatitis). In this conversation, we discuss Andrew's journey through global biotech leadership, why he chose to lead a French biotech company, the challenges of running a late-stage clinical business, and what makes Inventiva's approach so exciting. We also explore the strengths of the European biotech ecosystem, the milestones ahead for Inventiva, and the leadership lessons Andrew has learned throughout his career.